MiR-182 acts as an oncomiR in HCC cells through different targets, such as ephrinA5 and FOXO3a, while it enhances the cytotoxicity of NK cells potentially through its effect on NKG2D (22, 24, 46). This evidence concerns the gene KLRK1 and hepatocellular carcinoma.